NO20041792L - Peptider som virker bade som GLP-1-reseptoragonister og glukagonreseptorantagonister og deres farmakologiske fremgangsmater for anvendelse - Google Patents

Peptider som virker bade som GLP-1-reseptoragonister og glukagonreseptorantagonister og deres farmakologiske fremgangsmater for anvendelse

Info

Publication number
NO20041792L
NO20041792L NO20041792A NO20041792A NO20041792L NO 20041792 L NO20041792 L NO 20041792L NO 20041792 A NO20041792 A NO 20041792A NO 20041792 A NO20041792 A NO 20041792A NO 20041792 L NO20041792 L NO 20041792L
Authority
NO
Norway
Prior art keywords
glp
pharmacological methods
receptor antagonists
peptides acting
receptor agonists
Prior art date
Application number
NO20041792A
Other languages
English (en)
Norwegian (no)
Inventor
Clark Pan
James Whelan
Kevin Clairmont
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of NO20041792L publication Critical patent/NO20041792L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20041792A 2001-10-05 2004-05-03 Peptider som virker bade som GLP-1-reseptoragonister og glukagonreseptorantagonister og deres farmakologiske fremgangsmater for anvendelse NO20041792L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32773001P 2001-10-05 2001-10-05
PCT/US2002/031693 WO2003040309A2 (en) 2001-10-05 2002-10-04 Peptides acting as both glp-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use

Publications (1)

Publication Number Publication Date
NO20041792L true NO20041792L (no) 2004-07-02

Family

ID=23277790

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20041792A NO20041792L (no) 2001-10-05 2004-05-03 Peptider som virker bade som GLP-1-reseptoragonister og glukagonreseptorantagonister og deres farmakologiske fremgangsmater for anvendelse

Country Status (27)

Country Link
US (6) US7399745B2 (de)
EP (1) EP1436330A4 (de)
JP (1) JP2005508639A (de)
KR (1) KR20050034580A (de)
CN (1) CN1326876C (de)
AR (1) AR036711A1 (de)
BR (1) BR0213132A (de)
CA (1) CA2462462A1 (de)
CO (1) CO5570710A2 (de)
DO (1) DOP2002000475A (de)
EC (2) ECSP024346A (de)
HN (1) HN2002000282A (de)
HR (1) HRP20040327A2 (de)
HU (1) HUP0401797A2 (de)
IL (1) IL160706A0 (de)
MA (1) MA26228A1 (de)
MX (1) MXPA04002140A (de)
MY (1) MY138267A (de)
NO (1) NO20041792L (de)
NZ (1) NZ532685A (de)
PE (1) PE20030850A1 (de)
PL (1) PL368760A1 (de)
RU (1) RU2334761C2 (de)
SG (2) SG149693A1 (de)
UY (1) UY27469A1 (de)
WO (1) WO2003040309A2 (de)
ZA (1) ZA200403322B (de)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006501820A (ja) * 2002-09-06 2006-01-19 バイエル・フアーマシユーチカルズ・コーポレーシヨン 修飾ｇｌｐ−１受容体アゴニストおよびそれらの薬理学的使用法
JP2006520818A (ja) 2003-03-19 2006-09-14 イーライ リリー アンド カンパニー ポリエチレングリコール結合ｇｌｐ−１化合物
US20050124550A1 (en) * 2003-06-18 2005-06-09 Peri Krishna G. Compounds that modulate the glucagon response and uses thereof
ATE461217T1 (de) * 2003-12-18 2010-04-15 Novo Nordisk As Glp-1-verbindungen
TW200643033A (en) * 2005-03-08 2006-12-16 Chugai Pharmaceutical Co Ltd Conjugate of water-soluble modified hyaluronic acid and glp-1 analogue
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
US8603972B2 (en) 2005-03-18 2013-12-10 Novo Nordisk A/S Extended GLP-1 compounds
CA2913805A1 (en) 2005-11-07 2007-05-18 Indiana University Research And Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
TWI430806B (zh) 2006-09-13 2014-03-21 Smithkline Beecham Corp 用於投與長效降血糖藥劑之方法
RU2477286C2 (ru) * 2007-01-05 2013-03-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн АНАЛОГИ ГЛЮКАГОНА, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ РАСТВОРИМОСТЬЮ В БУФЕРАХ С ФИЗИОЛОГИЧЕСКИМ ЗНАЧЕНИЕМ pH
CA2677932A1 (en) 2007-02-15 2008-08-21 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
WO2008098693A2 (en) * 2007-02-16 2008-08-21 Bayer Healthcare Ag Convergent synthesis of glp-1
ES2509883T3 (es) 2007-10-30 2014-10-20 Indiana University Research And Technology Corporation Antagonistas de glucagón
MX2010004298A (es) * 2007-10-30 2010-05-03 Univ Indiana Res & Tech Corp Compuestos que exhiben actividad antagonista de glucagon y agonista de glp-1.
CA2707448C (en) * 2007-12-11 2014-10-14 Cadila Healthcare Limited Peptidomimetics with glucagon antagonistic and glp-1 agonistic activities
EP2249853A4 (de) * 2008-01-30 2012-12-26 Univ Indiana Res & Tech Corp Peptid-prodrugs auf esterbasis
AR070844A1 (es) 2008-03-27 2010-05-05 Lilly Co Eli Fragmento fab o anticuerpo monoclonal humanizado que comprende el fragmento fab, y su uso para la manufactura de un medicamento antagonista del polipeptido del receptor de glucagon para el tratamiento o prevencion de diabetes de tipo 1 o 2
AR072160A1 (es) * 2008-06-17 2010-08-11 Univ Indiana Res & Tech Corp Co-agonistas del receptor de glucagon/glp-1
US8450270B2 (en) * 2008-06-17 2013-05-28 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility and stability in physiological pH buffers
CN102105159B (zh) * 2008-06-17 2015-07-08 印第安纳大学研究及科技有限公司 基于gip的混合激动剂用于治疗代谢紊乱和肥胖症
MX2011000847A (es) 2008-08-06 2011-02-25 Novo Nordisk Healthcare Ag Proteinas conjugadas con eficacia prolongada in vivo.
PT2373681T (pt) 2008-12-10 2017-04-11 Glaxosmithkline Llc Composições farmacêuticas de albiglutida
PE20120332A1 (es) 2008-12-19 2012-04-14 Univ Indiana Res & Tech Corp Profarmacos de peptido de la superfamilia de glucagon basado en amida
MX2011007736A (es) 2009-01-22 2011-09-06 Novo Nordisk Healthcare Ag Compuestos de hormona del crecimiento estables.
EP2443146B1 (de) 2009-06-16 2016-10-05 Indiana University Research And Technology Corporation Gip-rezeptor-aktive glucagon-verbindungen
WO2011015649A1 (en) 2009-08-06 2011-02-10 Novo Nordisk Health Care Ag Growth hormones with prolonged in-vivo efficacy
GB0917072D0 (en) 2009-09-29 2009-11-11 Univ Ulster Peptide analogues of glucagon for diabetes therapy
US8703701B2 (en) 2009-12-18 2014-04-22 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
EP2460527A1 (de) 2010-01-21 2012-06-06 Sanofi Pharmazeutische Zusammensetzung zur Behandlung eines metabolischen Syndroms
RS59459B1 (sr) 2010-01-22 2019-11-29 Novo Nordisk Healthcare Ag Hormoni rasta sa produženom in-vivo efikasnošću
MX338357B (es) 2010-01-22 2016-04-13 Novo Nordisk Healthcare Ag Compuestos estables de la hormona de crecimiento.
KR20120123443A (ko) 2010-01-27 2012-11-08 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 대사 장애 및 비만 치료용 글루카곤 길항제-ｇｉｐ 항진제 콘쥬게이트
US8691763B2 (en) 2010-05-04 2014-04-08 Glaxosmithkline Llc Methods for treating or preventing cardiovascular disorders and providing cardiovascular protection
JP6050746B2 (ja) 2010-05-13 2016-12-21 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation Ｇタンパク質共役受容体活性を示すグルカゴンスーパーファミリーのペプチド
MX2012013001A (es) 2010-05-13 2013-02-26 Univ Indiana Res & Tech Corp Peptidos de la superfamilia de glucagon que presentan actividad del receptor nuclear de hormonas.
EP2588126A4 (de) 2010-06-24 2015-07-08 Univ Indiana Res & Tech Corp Amidbasierte glucagon-superfamilien-peptid-prodrugs
US8507428B2 (en) 2010-12-22 2013-08-13 Indiana University Research And Technology Corporation Glucagon analogs exhibiting GIP receptor activity
CA2828761C (en) * 2011-03-04 2017-04-04 Becton, Dickinson And Company Blood collection device containing lysophospholipase inhibitor
RS56173B1 (sr) 2011-06-22 2017-11-30 Univ Indiana Res & Tech Corp Koagonisti receptora za glukagon/glp-1 receptora
KR20140043793A (ko) 2011-06-22 2014-04-10 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 글루카곤/glp-1 수용체 공동-작용물질
EP2548570A1 (de) 2011-07-19 2013-01-23 Sanofi Pharmazeutische Zusammensetzung zur Behandlung eines metabolischen Syndroms
JP6324315B2 (ja) 2011-11-17 2018-05-16 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ グルココルチコイド受容体の活性を示すグルカゴンスーパーファミリーのペプチド
CN104583232B (zh) 2012-06-21 2018-04-13 印第安纳大学研究及科技有限公司 展现gip受体活性的胰高血糖素类似物
JP6538645B2 (ja) 2013-03-14 2019-07-03 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ インスリン‐インクレチン複合物
US11045523B2 (en) 2013-04-05 2021-06-29 Novo Nordisk Healthcare Ag Formulation of growth hormone albumin-binder conjugate
CR20160376A (es) 2014-01-20 2016-10-07 Hanmi Pharm Ind Co Ltd Insulina de acción prolongada y uso de la misma
WO2015168135A1 (en) 2014-04-28 2015-11-05 The Trustees Of The University Of Pennsylvania Novel thioamide-modified peptides and uses thereof
WO2015183984A2 (en) * 2014-05-28 2015-12-03 Stealth Peptides International, Inc. Therapeutic compositions including tocopherol and uses thereof
AR100639A1 (es) 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
AR100695A1 (es) 2014-05-30 2016-10-26 Hanmi Pharm Ind Co Ltd Composición para el tratamiento de diabetes mellitus que comprende insulina y un agonista dual glp-1 / glucagón
JP6666899B2 (ja) 2014-07-21 2020-03-18 アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニヴァーシティー オブ アリゾナ Ａｎｇ−（１−７）誘導体オリゴペプチド、ならびにそれを使用および作製するための方法
US10183055B2 (en) 2014-07-21 2019-01-22 Arizona Board Of Regents On Behalf Of The University Of Arizona Ang-(1-7) derivative oligopeptides for the treatment of pain and other indications
CN108271356A (zh) 2014-09-24 2018-07-10 印第安纳大学研究及科技有限公司 肠降血糖素-胰岛素缀合物
UY36870A (es) 2015-08-28 2017-03-31 Hanmi Pharm Ind Co Ltd Análogos de insulina novedosos
JP7158378B2 (ja) 2016-09-23 2022-10-21 ハンミ ファーマシューティカル カンパニー リミテッド インスリン受容体との結合力が減少された、インスリンアナログ及びその用途
KR102629006B1 (ko) 2017-03-23 2024-01-25 한미약품 주식회사 인슐린 수용체와의 결합력이 감소된 인슐린 아날로그의 결합체 및 이의 용도
WO2019160940A1 (en) 2018-02-13 2019-08-22 Ligand Pharmaceuticals Incorporated Glucagon receptor antagonists
US20220056077A1 (en) 2018-12-04 2022-02-24 Københavns Universitet Dual agonist glp-1 and neurotensin fusion peptide
US12591761B2 (en) 2018-12-05 2026-03-31 Shape Security, Inc. Execution of trained neural networks using a database system
US11934931B2 (en) * 2018-12-17 2024-03-19 Shape Security, Inc. Decision tree training using a database system
WO2020254479A1 (en) * 2019-06-18 2020-12-24 Fresenius Kabi Ipsum S.R.L. Process for the manufacture of glucagon
US12406209B1 (en) 2019-06-28 2025-09-02 Shape Security, Inc. Decision tree training using a database system
CN113728013B (zh) 2020-01-11 2022-06-14 北京质肽生物医药科技有限公司 Glp-1和fgf21的融合蛋白的缀合物
CN113461785B (zh) * 2021-04-13 2022-10-14 湖南中晟全肽生化有限公司 Glp-1受体激动剂及其应用
WO2023284822A1 (en) 2021-07-14 2023-01-19 Beijing Ql Biopharmaceutical Co., Ltd. Fusion polypeptides for metabolic disorders
KR20260010739A (ko) 2023-05-11 2026-01-21 유니버시티 하스피탈즈 클리블랜드 메디컬 센터 항불안 치료

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE164852T1 (de) * 1990-01-24 1998-04-15 Douglas I Buckley Glp-1-analoga verwendbar in der diabetesbehandlung
EP0567562B1 (de) * 1991-01-17 1996-03-13 Zymogenetics, Inc. Verfahren zum nachweis von glucagon-antagonisten
US5846747A (en) * 1992-03-25 1998-12-08 Novo Nordisk A/S Method for detecting glucagon-like peptide-1 antagonists and agonists
US5480867A (en) * 1993-12-29 1996-01-02 The Rockefeller University Glucagon analogs with serine replacements
FI974437A7 (fi) * 1995-06-06 1997-12-05 Pfizer Substituoituja N-(indoli-2-karbonyyli)amideja ja johdannaisia glykogee nifosforylaasi-inhibiittoreina
US5782802A (en) * 1996-03-22 1998-07-21 Vitajet Corporation Multiple use needle-less hypodermic injection device for individual users
US6232310B1 (en) * 1999-03-12 2001-05-15 Novo Nordisk A/S Fused 1,4-thiazine-2-carbonitrile derivatives, their preparation and use
US7041646B2 (en) * 2001-10-05 2006-05-09 Bayer Pharmaceuticals Corporation Methods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists

Also Published As

Publication number Publication date
HN2002000282A (es) 2002-12-12
US7488714B2 (en) 2009-02-10
US20060003418A1 (en) 2006-01-05
IL160706A0 (en) 2004-08-31
SG158736A1 (en) 2010-02-26
US20060003934A1 (en) 2006-01-05
US7494978B2 (en) 2009-02-24
CN1564828A (zh) 2005-01-12
WO2003040309A2 (en) 2003-05-15
ECSP045094A (es) 2004-06-28
MA26228A1 (fr) 2004-07-01
CN1326876C (zh) 2007-07-18
US7399745B2 (en) 2008-07-15
AR036711A1 (es) 2004-09-29
DOP2002000475A (es) 2003-06-30
CA2462462A1 (en) 2003-05-15
PE20030850A1 (es) 2003-10-31
SG149693A1 (en) 2009-02-27
WO2003040309A3 (en) 2003-12-18
UY27469A1 (es) 2003-04-30
US20050288248A1 (en) 2005-12-29
MXPA04002140A (es) 2005-03-07
US20060003417A1 (en) 2006-01-05
US7488715B2 (en) 2009-02-10
CO5570710A2 (es) 2005-10-31
HUP0401797A2 (en) 2006-08-28
JP2005508639A (ja) 2005-04-07
MY138267A (en) 2009-05-29
ZA200403322B (en) 2005-05-03
EP1436330A2 (de) 2004-07-14
HK1073117A1 (zh) 2005-09-23
EP1436330A4 (de) 2006-01-18
KR20050034580A (ko) 2005-04-14
NZ532685A (en) 2006-02-24
RU2334761C2 (ru) 2008-09-27
BR0213132A (pt) 2004-10-19
US20050153890A1 (en) 2005-07-14
US7488716B2 (en) 2009-02-10
RU2004114243A (ru) 2005-05-10
ECSP024346A (es) 2003-05-26
HRP20040327A2 (en) 2007-11-30
PL368760A1 (en) 2005-04-04
US20060003419A1 (en) 2006-01-05

Similar Documents

Publication Publication Date Title
NO20041792L (no) Peptider som virker bade som GLP-1-reseptoragonister og glukagonreseptorantagonister og deres farmakologiske fremgangsmater for anvendelse
NO20030471D0 (no) Karboksamidforbindelser og deres anvendelse som antagonister for en 11CBY-reseptor
NO20032277D0 (no) Aminotiazoler og deres anvendelse som adenosinreseptorantagonister
NO20043536L (no) Fluorsubstituerte sykloalkanoindoler og deres anvendelse som prostaglandin D2-reseptorantagonister
NO20032797L (no) Substituerte pyridoindoler som serotonin agonister og antagonister
NO20031952L (no) 3-aroylinderivater og deres anvendelse som CB2 reseptoragonister
AU2003273300A8 (en) Modified glp-1 receptor agonists and their pharmacological methods of use
DK1309559T3 (da) 4-phenyl-pyridinderivater som neurokinin-1-receptorantagonister
DK1394150T3 (da) 4-phenylpyridinderivater og deres anvendelse som NK-1-receptorantagonister
DK1558615T3 (da) Purin-forbindelser og deres anvendelse som cannabinoid receptor ligander
DK1446379T3 (da) Arylanilin-beta2-adrenergiske receptoragonister
NO20041008L (no) Karbazolderivater og anvendelse derav som NPY5 reseptor antagonister
DK2208727T3 (da) Diarylethere som opioidreceptorantagonister
AU5716901A (en) G protein coupled receptor (gpcr) agonists and antagonists and methods of activating and inhibiting gpcr using the same
CY2015002I1 (el) Glp-1 αναλογα πρωτεϊνων συντηξης
DK1501809T3 (da) Trizolderivater som tachykininreceptorantagonister
NO20020314D0 (no) 2-arylimino-2,3-dihydrotiazoler og deres anvendelse som ligander for somatostatin-reseptorer
EP1361872A4 (de) Neue lysophosphatsäurerezeptor-agonisten und -antagonisten
DK1305319T3 (da) 4-phenyl-pyridinderivater som neurokinin-1-receptorantagonister
NO20025640L (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptorantagonister
NO995482D0 (no) Ergolinderivater og deres anvendelse som somatostatinreseptorantagonister
NO20043366L (no) Kortikotropinfrigjorende faktor-2 reseptoragonister
NO20040499L (no) Substituerte pyridin-4-oner og deres andvendelse som gonadotropin-frigjorende hormon reseptor antagonister.
NO20025762L (no) Bicykliske cykloheksylaminer og anvendelse derav som NMDA- reseptorantagonister
AU2002351730A1 (en) Glucagon receptor antagonists/inverse agonists

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application